Updated interpretation of your pharmacogenetic data on 5th June 2020

02 Jun Updated interpretation of your pharmacogenetic data on 5th June 2020

As leaders in making pharmacogenetics clinically relevant and useful in primary care, we ensure that we keep up to date with research. Your genes have not changed, but new research evidence has allowed us to interpret them more precisely. This new interpretation may impact some of the medication options available to you.

As new pharmacogenetic research is published, it is continuously being assessed by an international organization (CPIC) who produce guidelines for health care providers and companies like ourselves to use. Because TreatGx is a software program, GenXys can take those new guideline recommendations and update the software regularly.

There are two genes impacted by changes to the guidelines: CYP2D6 and CYP2C9.

What do the new changes mean for TreatGx users?

Altered medication information will be shown in our software for medications affected by CYP2D6. Some people who were previously classified as having normal metabolism for several drugs may now be classified as intermediate metabolizers.

For medications affected by CYP2C9, some people who were previously classified as having poor metabolism for several drugs may now be classified as intermediate metabolizers.

See below for a list of medications that are affected by these changes.

The bottom line is that we have reinterpreted ALL your pharmacogenetics for all conditions and medications, using the latest guidelines on these two genes to do so. An update containing that information will be happening soon, and affected users will be notified by email.

Example case:

Clare has attention deficit hyperactivity disorder (ADHD) and had the TreatGx^plus pharmacogenetic test done in August 2019. When her results arrived, she used the TreatGx medication decision support software, which included the interpretation of her genetic test results, and saw that she was classified as a CYP2D6 normal metabolizer. One of the medications that was listed as a third line option for her was desipramine and it said:

After the recent update, she looks again at the TreatGx medication decision support software and sees that she is now classified as a CYP2D6 intermediate metabolizer. This is because of the new evidence that has been published. Now when she looks at desipramine, it has a different suggested dose due to the reclassification of her metabolizer status:

If you are taking medications and they are working well, then it is likely that no changes are required. You should only change medications upon the advice of your health professionals.

GenXys is committed to helping you use your pharmacogenetic information to improve your health outcomes and making sure the clinical interpretation we use is as up to date as possible. If you have any questions, please contact us at info@genxys.com

Medications affected by new evidence & interpretation for CYP2D6 or CYP2C9:

Alprazolam

Atomoxetine

Atomoxetine

Bromazepam

Celecoxib

Chlordiazepoxide

Clobazam

Clomipramine

Clonazepam

Clorazepate

Desipramine

Desipramine

Diazepam

Diclofenac

Flurazepam

Flurbiprofen

Ibuprofen

Imipramine

Lorazepam

Meloxicam

Nitrazepam

Nortriptyline

Oxazepam

Phenytoin

Piroxicam

Tamoxifen

Temazepam

Tenoxicam

Triazolam

Trimipramine

Venlafaxine